The AstraZeneca Cancer Support Network (AZ CSN) provides comprehensive, up-to-date medical and reimbursement information for AstraZeneca oncology products. The AZ CSN is available is available to patients and health care professionals.
Source: Mediwire
By: AstraZeneca Pharmaceuticals LP
The AstraZeneca Cancer Support Network (AZ CSN) provides comprehensive, up-to-date medical and reimbursement information for AstraZeneca oncology products. The AZ CSN is available to patients and health care professionals.
The AstraZeneca Cancer Support Network can help your patients by...
The AstraZeneca Cancer Support Network (AZCSN) is provided to health care professionals and patients for informational purposes only. The laws, regulations, and policies pertaining to coverage and reimbursement are subject to change and do change from time to time. Information provided by the AZCSN does not constitute medical or legal advice and is not intended to be a substitute for a consultation with a licensed health care provider, your legal counsel, or applicable third-party payer(s). AstraZeneca reserves the right to modify the AZCSN at any time without notice. For information, please contact the AstraZeneca Cancer Support Network at 1-866-99-AZCSN (1-866-992-9276), Monday through Friday 8:00 AM - 8:00 PM ET. Or, click on the link below to visit the AZCSN Web site. www.AZCSN.net
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More